Overview
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AbbottTreatments:
Atomoxetine Hydrochloride
Criteria
Inclusion Criteria:- Meet criteria for attention-deficit/hyperactivity disorder
- Have voluntarily signed an informed form
- Are between 18 and 60 years of age
- Will use contraceptive methods during the study
- Women must not be pregnant or breast-feeding
- Must be in generally good health
- Are fluent in English
Exclusion Criteria:
- They have a current or past diagnosis of schizoaffective disorder, schizophrenia,
obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic
disorder or mental retardation
- They have a current diagnosis of major depressive episode, generalized anxiety
disorder (GAD), or post-traumatic stress disorder (PTSD) or has a clinically
significant sleep disorder requiring treatment
- They require ongoing treatment or expected treatment with any psychotropic medication,
including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood
stabilizers, nicotine replacement therapies or varenicline
- They require ongoing treatment or expected treatment with Coumadin
- They failed to respond to two or more adequate trials of FDA-approved ADHD medication
- They have taken atomoxetine during the last 3 months
- They have violent, homicidal or suicidal ideation
- They have a significant history of medical diagnoses, seizure disorder, Tourette's
syndrome, traumatic brain injury, or a central nervous system (CNS) disease, excluding
ADHD
- They have a urine drug screen that is positive for alcohol or drugs of abuse
- They have a history of substance or alcohol disorder during the last 3 months